Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017
September 05 2017 - 7:45AM
Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing
novel, first-in-class therapeutics to address the medical needs of
patients with kidney and vascular diseases, today announced that
Company management will present at the Baird 2017 Global Healthcare
Conference on September 7, 2017 at 9:40 a.m. ET in New York, NY.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of
patients with kidney and vascular diseases through the development
of novel, first-in-class therapeutics. Proteon's lead product
candidate, vonapanitase, is an investigational drug intended to
improve hemodialysis vascular access outcomes. Proteon is currently
enrolling patients in PATENCY-2, a Phase 3 clinical trial
evaluating vonapanitase in patients with chronic kidney disease
(CKD) undergoing surgical creation of a radiocephalic arteriovenous
fistula for hemodialysis. Proteon is also evaluating vonapanitase
in a Phase 1 clinical trial in patients with peripheral artery
disease (PAD). For more information, please visit
www.proteontx.com.
Investor ContactGeorge Eldridge, Proteon
Therapeutics, Senior Vice President and Chief Financial
Officer781-890-0102geldridge@proteontherapeutics.com
Media ContactAnn Stanesa, Ten
Bridge
Communications617-230-0347proteon@tenbridgecommunications.com
Proteon Therapeutics (NASDAQ:PRTO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Proteon Therapeutics (NASDAQ:PRTO)
Historical Stock Chart
From Sep 2023 to Sep 2024